US FDA classifies dressings containing pDADMAC as Class II
This article was originally published in RAJ Devices
The US Food and Drug Administration is classifying wound dressings that contain the additive poly (diallyl dimethyl ammonium chloride) as Class II devices and has issued a guidance document on special controls that must be followed by manufacturers intending to market such products1-3.
You may also be interested in...
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include eight new products, including Roche's Rozlytrek (entrectinib) for the histology-independent indication of treatment of patients with NTRK fusion-positive solid tumors, and for treating patients with ROS1-positive advanced non-small cell lung cancer. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
International regulators have agreed on primary endpoints that would be suitable for assessing the clinical benefit of an investigational therapeutic for COVID-19 and support regulatory approval.